Real-world comparison of major bleeding and associated costs among treatment-naïve nonvalvular atrial fibrillation patients initiating apixaban or warfarin

Alpesh Amin(University of California, Irvine), Jeffrey Trocio(Pfizer (United States)), Onur Başer(STATinMED (United States)), Mario Mendoza(Pfizer (United States)), Shalabh Singhal(Integrated BioTherapeutics (United States)), Allison Keshishian(STATinMED (United States)), Lin Xie(STATinMED (United States)), Chinmay Patel, K Price, Kate M. O’Dell, L. Vo, Jack Mardekian(Pfizer (United States))
MEF University Institutional Repository (MEF University)
January 1, 2016
Cited by 0

Related Papers

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long‐Term Warfarin Therapy
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2007|93
Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
|Journal of Clinical Oncology|2019|36
LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
|Annals of the Rheumatic Diseases|2022|19